Clinical trials: Urinary Complications
Urinary Incontinence
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
This is a placebo-controlled, double-blind study to evaluate the safety and efficacy of two doses of DR-3001 in women with overactive bladder who have symptoms of predominant or pure urge incontinence, urinary urgency and…
- Trial name
- NCT00196404
- Testing
- DR-3001a, DR-3001b
- Where
- 48 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Duramed Research
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Non-Muscle Invasive Bladder Neoplasms
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy.
- Trial name
- NCT05316155
- Testing
- Erdafitinib Intravesical Delivery System
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 235 people
- Sponsor
- Janssen Research & Development, LLC
Transitional Cell Carcinoma, Bladder Neoplasms
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium.
- Conditions
- Transitional Cell Carcinoma, Bladder Neoplasms, Kidney Neoplasms, Ureter Neoplasms
- Trial name
- NCT00101608
- Testing
- vinflunine
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
This study is designed to estimate the effect of fluconazole (200 mg BID for 2 days), a moderate CYP3A4 inhibitor on the pharmacokinetics of a single 8 mg oral dose of fesoterodine in healthy adult subjects.
- Trial name
- NCT00911235
- Testing
- Fesoterodine, fesoterodine plus fluconazole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Urinary Urge Incontinence (UUI), Urinary Frequency (UF)
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the Axonics SNM System INS Model 5101.
- Conditions
- Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
- Trial name
- NCT06789406
- Testing
- Axonics SNM System INS Model 5101 (R20)
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 55 people
- Sponsor
- Axonics, Inc.
Overactive Bladder
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.
- Trial name
- NCT00658684
- Testing
- fesoterodine fumarate
- Where
- 12 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Pfizer
Stress Urinary Incontinence
Stress Incontinence Trial With Elitone Device
This is a randomized controlled study in which subjects are assigned to either a treatment group or a control (sham) group. Pre- and post-study outcome measures evaluate the change in incontinence episodes on women with…
- Trial name
- NCT03782116
- Testing
- Transcutaneous electrical stimulation (Elitone)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Elidah, Inc.
Ureteral Calculi, Kidney Stones
Study of Silodosin to Facilitate Passage of Urinary Stones
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
- Conditions
- Ureteral Calculi, Kidney Stones, Urolithiasis
- Trial name
- NCT01144949
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 239 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder, Urinary Incontinence
Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence
The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.
- Conditions
- Overactive Bladder, Urinary Incontinence, Children
- Trial name
- NCT00603343
- Testing
- Mictonetten 5 mg, coated tablet
- Volunteers
- 303 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Kidney Transplant, Kidney Failure
Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors.
- Conditions
- Kidney Transplant, Kidney Failure, Renal and Urinary Tract Therapeutic Procedures, End Stage Renal Disease (ESRD)
- Trial name
- NEWHOPE (NCT07792317)
- Testing
- Omnisol organ preservation solution
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Vivalyx GmbH
Overactive Bladder
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
- Trial name
- INTIMO2 (NCT02674269)
- Testing
- 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel
- Where
- 2 sites in Israel
- Sponsor
- UroGen Pharma Ltd.
Urinary Bladder, Overactive
A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers
This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 2-cohort, 3-period study to characterize the pharmacokinetics (process by which drug fesoterodine is…
- Trial name
- NCT01566760
- Testing
- fesoterodine fumarate
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Urination Disorders
An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.
The purpose of this study is to evaluate the safety and effectiveness of oxybutynin extended release tablets 10 mg plus tamsulosin HCl 0.4 mg in the treatment of lower urinary tract symptoms as measured by change of the total…
- Trial name
- NCT00338624
- Testing
- oxybutynin chloride extended release
- Volunteers
- 420 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Bladder Neoplasms, Ureteral Neoplasms
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma…
- Conditions
- Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Carcinoma, Transitional Cell
- Trial name
- NCT00077688
- Testing
- TOCOSOL Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Achieve Life Sciences
Urinary Bladder, Overactive
FemPulse Therapy for Overactive Bladder in Women
The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.
- Trial name
- EVANESCE-OAB (NCT03784170)
- Testing
- FemPulse System
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- FemPulse Corporation
Urinary Bladder, Overactive
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency.
- Trial name
- NCT01302054
- Testing
- Fesoterodine 8 mg
- Where
- 176 sites in United States, Bulgaria and 13 more
- Volunteers
- 990 people
- Sponsor
- Pfizer
Urinary Incontinence, Urinary Bladder, Overactive
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder…
- Trial name
- NCT02010788
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 523 people
- Sponsor
- Allergan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.